Gene Targeting in Embryonic Stem Cells Scores a Knockout in Stockholm  by Mak, Tak Wah
Leading Edge
EssayGene Targeting in Embryonic Stem Cells 
Scores a Knockout in Stockholm
Tak Wah Mak1,*
1Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, and the Departments of Medical Biophysics 
and Immunology, University of Toronto, 620 University Avenue, Toronto, Ontario, Canada M5G 2C1
*Correspondence: tmak@uhnres.utoronto.ca
DOI 10.1016/j.cell.2007.11.033
The 2007 Nobel Prize in Physiology or Medicine has been awarded to Mario Capecchi, 
Martin Evans, and Oliver Smithies for developing specific gene modification techniques 
and mouse embryonic stem cell technology that, when combined, enable the creation 
of “knockout” mice. Analyses of these mutant animals have revolutionized the elucida-
tion of gene functions, and these mice have proved to be valuable models of numerous 
human diseases.Exactly a century ago, Clarence Cook 
Little, a graduate student in William 
Ernest Castle’s laboratory at Harvard 
University, clung to the belief that the 
lowly mouse could one day become a 
model in which to study human physi-
ology and disease. Little and Castle 
realized that, to achieve this goal, 
they had to develop mouse strains 
that were more genetically homoge-
neous. Backed by Castle’s expertise 
as a respected authority on mamma-
lian Mendelian genetics, Little com-
menced interbreeding wild mice in 
1909. He hoped to obtain animals with 
a better defined genetic background 
that would simplify laboratory studies 
of mammalian traits. The success of 
this program marked the beginning of 
inbred mouse genetics.
This year, we celebrate a century 
of advances in a subject that has per-
meated every field of physiology and 
medicine: animal genetics. We rejoice 
that the Nobel Assembly at the Karo-
linska Institute in Sweden has awarded 
the 2007 Nobel Prize in Physiology or 
Medicine to three individuals who pio-
neered techniques of gene targeting 
in murine embryonic stem (ES) cells. 
The work of these researchers revolu-
tionized the study of mouse genetics 
and has made it possible for scientists 
around the world to generate geneti-
cally defined mouse mutants for the 
study of functions of individual genes. 
The 2007 Nobel Prize winners are Mario 
Capecchi of the University of Utah, Martin Evans of Britain’s Cardiff Uni-
versity, and Oliver Smithies of the Uni-
versity of North Carolina at Chapel Hill. 
The citation reads: “For their discover-
ies of principles for introducing specific 
gene modifications in mice by the use 
of embryonic stem cells.” This year’s 
Nobel Prize nicely complements last 
year’s award to Andrew Fire of Stanford 
University and Craig Mello of the Uni-
versity of Massachusetts at Worcester, 
who jointly received the 2006 Nobel 
Prize for Physiology or Medicine for 
their discovery of  microRNAs. The prin-
ciples by which microRNAs function 
have been exploited to develop inter-
ference RNAs that permit the silencing 
of gene functions at will and with rela-
tive ease.
Why Study Mice?
Scientists study biology to learn about 
physiology and investigate mammals 
to learn about human behavior, devel-
opment, and pathophysiology. At the 
cellular and molecular levels, there 
are significant similarities between 
human cells and those of other multi-
cellular or even unicellular organisms. 
However, at the organismal level, 
humans share extensive physiologi-
cal characteristics only with other pri-
mates. Nevertheless, many features 
of human development and biology 
are closely analogous to those of 
fast-breeding and easily maintained 
rodents. Embryonic development, 
organogenesis, hematopoiesis, and Cell 131, Deceimmune responses are all strikingly 
comparable at the physiological level 
in humans and mice. Perhaps this 
should not be surprising, as 99% of 
the genes in these two species are 
shared. Thus, the use of the mouse 
as a model for studying human devel-
opment and disease is an approach 
that can be readily justified.
The Early Days of Mouse Genetics
The early pioneers of mouse genet-
ics were well aware of the possibili-
ties of using rodents to learn more 
about human biology and genetics. 
Little, Leonell Strong, E. Carlton Mac-
Dowell, and others spent almost two 
decades systematically intercross-
ing mice captured from the wild and 
generating scores of inbred strains. A 
dozen of these lines are still commonly 
used in laboratories around the globe, 
including the Balb/c, B6, B10, C3H, 
CBA, and DBA strains. Comparative 
investigations of these multiple lines 
of mice derived from a mixture of 
forebears from relatively diverse geo-
graphic locations have allowed scien-
tists to probe the extent of mammalian 
genetic diversity. Many of the mouse 
strains created by these researchers, 
as well as other rodent mutants, were 
eventually consolidated at the Jack-
son Laboratory in Maine, which Little 
founded in 1929. The Jackson Labora-
tory became and remains to this day 
one of the meccas of rodent genetics, 
devoted to the unearthing and housing mber 14, 2007 ©2007 Elsevier Inc. 1027
of interesting substrains and mutants. 
Back in the 1930s, investigations of 
the Jackson Laboratory’s collection 
of mutants yielded major advances in 
our understanding of many aspects 
of mammalian bodily processes. For 
example, Peter Gorer and George 
Davis Snell, another student of Castle, 
joined the Jackson Laboratory and 
devoted 25 years almost exclusively 
to studies of mouse histocompatibility 
genes. In the course of these stud-
ies, Snell discovered the H-2 complex 
(containing the MHC genes) that gov-
erns transplant rejection and immune 
responses. For this work, Snell shared 
the 1980 Nobel Prize in Physiology or 
Medicine with Jean Dausset and Baruj 
Benacerraf.
Little’s trailblazing efforts were fol-
lowed by the heroic labors of many 
who undertook the arduous task of 
creating and characterizing mouse 
models of human diseases. Although 
the initial objective was to study tum-
origenesis in mice, the intercrossing 
of millions of animals over several 
decades also produced rare exam-
ples of mice exhibiting symptoms of 
anemia, immunodeficiency, fragile X 
syndrome, Alzheimer’s dementia, or 
obesity (among others). The work of 
many dedicated individuals contrib-
uted to this cause, including the pio-
neering research of Elizabeth Russell, 
Sheldon Bernstein, and Jane Baker 
on mouse anemia; the landmark 
experiments of Douglas Coleman on 
obesity; and Donald Bailey’s ground-
breaking development of recombi-
nant inbred strains that facilitate gene 
mapping. William and Lee Russell of 
the Oak Ridge National Laboratory 
in Tennessee, as well as Mary Lyon 
and Bruce Cattanach of the Atomic 
Energy Research Establishment in 
Hartwell in England, led research 
teams that formalized  irradiation and 
other mutagenesis techniques that 
made it easier to study basic ques-
tions in mouse genetics. However, 
despite these prodigious efforts, 
elucidation of the genetic causes 
of physiological phenomena such 
as cancer and obesity proved to be 
exceedingly strenuous. One impedi-
ment to more rapid progress in these 
studies was the discovery that the 1028 Cell 131, December 14, 2007 ©200mice in question were genetically 
more closely related than was ideal. 
Underneath their ostensible diversity, 
these rodents actually arose from a 
relatively small number of ancestors 
derived from a limited number of orig-
inal sources. Even with the benefit of 
modern techniques of irradiation and 
chemical mutagenesis, the process of 
obtaining genetic variants via breed-
ing programs remains lengthy, costly, 
and labor intensive.
Molecular Biology Revolutionizes 
Mouse Genetics
With the dawn of the molecular biology 
era in the mid-1970s, it became pos-
sible to identify the molecular bases 
of the physiological and pathophysi-
ological variations observed in differ-
ent mouse strains and their mutants. 
However, early attempts to delineate 
these mutations at the molecular 
level required an enormous struggle 
and consumed years of demanding 
experimentation. Even with today’s 
technology, this type of “forward 
genetics” approach requires consid-
erable effort to pinpoint the molecular 
changes occurring in randomly gen-
erated mutants. We now know, as a 
result of two massive DNA sequenc-
ing projects carried out by Fernando 
Pardo-Manuel de Villena at the Uni-
versity of North Carolina and his col-
laborators at the Jackson Laboratory, 
as well as by David Cox of Perlegen 
Sciences Inc., that the genomes of 
the commonly used laboratory strains 
and several lines of wild mice differ by 
only a few million base pairs (Calla-
way, 2007). This amount of variation, 
which is unevenly distributed in the 
mouse genome, is considerably less 
than expected. The creation of addi-
tional rodent strains from stocks of a 
more diverse genetic background are 
currently in progress.
While the enterprise of mouse 
genetics was steadily advancing from 
the 1930s to the 1980s, the study of 
the genes themselves was undergo-
ing a revolution. By the late 1970s, the 
techniques of molecular biology were 
starting to deliver significant numbers 
of genes to biologists for study, and 
the need for a quick and easy means 
of generating defined mouse mutants 7 Elsevier Inc.became a priority. Solving this difficulty 
was never as dire in other species as 
it was in mammalian cells, for obvious 
reasons. Unicellular organisms such 
as bacteria and yeast, and even multi-
cellular species like the fruit fly Droso-
phila melanogaster and the nematode 
Caenorhabditis elegans, reproduce at 
a much faster rate than mammals and 
are much more amenable to mutagen-
esis. Mammalian geneticists dreamt 
of refining the techniques of “forward 
genetics” used to generate mutations 
in flies and worms and applying them 
to mammalian cells. A technology that 
went a long way to satisfying the desire 
of biologists to study the functions 
of specific genes in whole animals 
was the independent development 
of transgenic mice in the early 1980s 
by Rudolf Jaenisch of the Massachu-
setts Institute of Technology, Frank 
Ruddle of Yale University, and Ralph 
Brinster of the University of Pennsyl-
vania and Richard Palmiter of the Uni-
versity of Washington (among others) 
(Palmiter and Brinster, 1985). These 
mutant animals allowed researchers 
to assess a gene’s function by exam-
ining the effects of its overexpression 
in either a whole animal or a specific 
tissue. Thousands of such mice were 
produced and studied and the appli-
cation of this technology is still preva-
lent today. Nevertheless, despite the 
usefulness of transgenic mice, mam-
malian geneticists still sought a means 
of mutating a gene and observing the 
results of its loss of function in a whole 
animal. Thus, the goal was to gener-
ate somatic cell mutants or, better still, 
gene-targeted mice bearing specific 
alterations. The trick was to find a way 
to incorporate a defined mutation into 
the genome of a mammalian embryo 
that could then develop into a whole 
animal displaying the effects of that 
mutation.
From Multipotent Cell to Mutant 
Animal
The development of a whole animal 
from an embryo requires that the earli-
est embryonic cells be multipotent, that 
is, have the capacity to generate every 
cell type needed in the body. The multi-
potency of mammalian cells has fasci-
nated embryologists and biologists for 
Figure 1. How to Make a Knockout Mouse
The first step in generating a knockout mouse is the construction of the targeting vector. The 
targeting vector generally contains a copy of the genomic murine gene disrupted by the inser-
tion of a positive selection marker such as neomycin resistance (Neo). A negative drug selection 
gene is also often included. The targeting vector is then introduced into murine ES cells, usually 
by electroporation. Successive rounds of drug selection allow the isolation of ES cells that are 
homologous recombinants. Confirmation of the desired gene disruption is achieved by PCR and 
Southern blotting of the ES cell DNA. ES cells heterozygous for the gene disruption are then 
injected into mouse blastocysts to generate embryos that are transferred to pseudopregnant 
female mice. Chimeric progeny are born that show incorporation of the targeted gene into either 
somatic cells or the germline. Chimeric mice with germ cells bearing the targeted mutation are 
bred with wild-type mice to generate progeny heterozygous for the disruption. Intercrossing of 
these heterozygotes produces F1 progeny, one-quarter of which should be mutants homozygous 
for the targeted mutation: the classic knockout mouse. (Figure adapted from The Immune Re-
sponse: Basic and Clinical Principles by Tak W. Mak and Mary E. Saunders, 2006, published by 
Elsevier Academic Press, London, UK).Cell 131, Decedecades. In 1961, Ernest A. McCulloch 
and James E. Till at the Ontario Can-
cer Institute in Toronto discovered that 
a single bone marrow precursor cell 
capable of forming a colony in an irra-
diated recipient mouse could give rise 
to multiple lineages of hematopoietic 
cells (Till and McCulloch, 1961). This 
result clearly demonstrated that at least 
some mammalian progenitor cells had 
the ability to differentiate into cell types 
of different lineages and suggested that 
it might be possible to manipulate the 
course of organogenesis. These exper-
iments set the stage for the very ambi-
tious dream (at the time) of regenerat-
ing an entire animal by injecting a small 
number of multipotent cells into an 
early embryo. The ability to propagate 
in culture, or isolate from animals, pre-
cursor cells having the capacity to give 
rise to an entire mammal would allow 
researchers to manipulate the genetics 
of a whole animal. The first step in this 
direction came from the work of Roy 
Stevens at the Jackson Laboratory, G. 
Barry Pierce of the University of Colo-
rado, and Beatrice Mintz at the Fox 
Chase Institute in Philadelphia (among 
others). These researchers reported on 
studies in which teratocarcinoma cell 
lines were induced to differentiate into 
cells of various tissue types, yielding 
invaluable insights into the plasticity of 
multiple lineage commitment (Andrews, 
2002). However, teratocarcinoma cells 
could not be used to regenerate an 
entire animal because these cells are 
intrinsically tumorigenic. The break-
through came in 1981 when Evans 
and his colleagues and Gail Martin’s 
laboratory independently succeeded 
in developing ES cell lines (Evans and 
Kaufman, 1981; Martin, 1981). These 
cells, which were derived from an early 
murine blastocyst, grew indefinitely in 
tissue culture and retained their multi-
potency as long as they were cultured 
on feeder layers. When injected into a 
new blastocyst, these ES cells contrib-
uted to the developing murine embryo, 
resulting in the creation of a genetic 
mosaic. The chimeric embryos were 
then brought to term by implantation in 
a pseudopregnant female mouse (see 
Figure 1). This seminal work provided 
researchers with the opportunity to 
manipulate the genetics of a mammal mber 14, 2007 ©2007 Elsevier Inc. 1029
at the embryonic stage. The Evans lab 
provided further proof of this principle 
by introducing the DNA of a retroviral 
provirus into ES cells and documenting 
the transmission of this foreign DNA 
through multiple generations of mice 
(Robertson et al., 1986).
Despite these triumphs, technical 
challenges remained in consistently 
sustaining ES cells in their multipo-
tent state in culture. In 1988, Aus-
tin Smith and John Heath at Oxford 
University and their collaborators at 
the Genetics Institute in Boston, as 
well as Nicholas Gough of the Euro-
pean Molecular Biology Laboratory in 
Heidelberg, discovered that inclusion 
in the culture medium of the growth 
factor leukemia inhibitory factor (LIF) 
allowed ES cells to robustly retain 
their multipotency. With this diffi-
culty conquered, ES cell technology 
became well defined and reproduc-
ible. The ability to reliably maintain ES 
cells in culture has allowed investiga-
tors to work out the principles and 
mechanisms of stem cell self-renewal 
and to identify critical regulators of 
tissue/cell differentiation. However, 
back in the 1980s, the more important 
observation was that ES cells offered 
an unprecedented opportunity to 
view the physiological consequences 
of specific genetic changes such as 
point mutations, insertions, and dele-
tions. The next hurdle to overcome 
was finding a method of introducing 
such genetic alterations into a mam-
malian genome.
Homologous Recombination: 
Mutations to Order
It had long been known that bac-
teria and yeast could repair dam-
age to their DNA through a process 
known as homologous recombina-
tion. Homologous recombination is 
a natural route by which a stretch 
of mutated DNA can be exchanged 
with a functional copy of this region 
of the genome if there is extensive 
nucleotide similarity between the two 
DNA sequences. By the early 1980s, 
studies of the somatic recombination 
of gene segments of the B and T cell 
receptor genes had made it clear that 
mammalian cells could also carry out 
this mechanism of DNA sequence 1030 Cell 131, December 14, 2007 ©20exchange. However, it was not known 
whether this type of homologous 
recombination could be induced in 
mammalian cells through the intro-
duction of naked foreign DNAs, or 
whether such introduction would be 
efficient enough to permit the creation 
of specific genetic changes. The lab-
oratories of Capecchi and Smithies 
were the first to show that homolo-
gous recombination between plas-
mid DNAs could be detected when 
the plasmids were introduced into 
mammalian cells. These investigators 
also subsequently demonstrated that 
specific mutations could be incor-
porated into mammalian DNA via 
the introduction of a plasmid-based 
vector bearing foreign DNA. Surpris-
ingly, a reasonably high degree of 
recombination was observed even 
when the vector and the intended 
genomic target sequence showed 
only a few kilobases of homology. In 
1987, Capecchi’s group succeeded 
in mutating the HPRT gene in ES 
cells by gene targeting (Thomas and 
Capecchi, 1987). Independently, the 
introduction of a vector bearing the 
wild-type HPRT gene sequence was 
used to target and functionally cor-
rect a mutated HPRT gene in an ES 
cell (Doetschman et al., 1987). These 
efforts formally proved that homolo-
gous recombination could be used 
to modify the mammalian genome in 
a predetermined manner, paving the 
way for the creation of gene-targeted 
“knockout” mice.
A Universe of Knockout Mice
The combination of the technologies 
of ES cell manipulation and homolo-
gous recombination provided the 
powerful “reverse genetics” approach 
that had been long sought to gener-
ate genetically defined rodents for the 
study of mammalian physiology and 
pathophysiology. Dozens of labora-
tories dived into the arena and dis-
covered that, despite its complexity, 
the technology was relatively easy 
to master. Within a decade, over one 
thousand mutated mice were gener-
ated. In addition, the ability to manip-
ulate homologous recombination in 
mammalian cells energized the study 
of the molecular mechanisms under-07 Elsevier Inc.lying this process. Today, a veritable 
cottage industry of hundreds of labo-
ratories worldwide has produced an 
estimated 10,000 different types of 
genetically engineered mice. Further-
more, an international consortium has 
recently been formed with an eye to 
mutating all protein-encoding genes 
in the mouse genome using this tech-
nology. At this point, the bottleneck 
to progressing faster in defining gene 
functions lies in analyzing the phe-
notypes of these animals rather than 
creating them.
As the gene-targeting juggernaut 
gathered momentum in the mid-
1990s, results were accumulating 
that had far-reaching consequences. 
It was soon discovered that null gene-
targeted mutations, which disrupt 
gene function in every tissue of an 
animal, often precluded the study of a 
gene’s function in adult tissues. Thus, 
other genetic modifications in rodents, 
including deletions, insertions, inver-
sions, translocations, and point muta-
tions, were devised to study the rela-
tionship between a gene’s structure 
and its function. A further refinement 
of this approach was to conditionally 
delete or mutate genetic loci in an 
inducible fashion, such that specific 
genetic alterations could be turned 
“off” or “on” in a temporal or spatial 
manner. The technology to create 
these conditional mutations arose 
from an ingenious application of the 
bacteriophage enzyme Cre recom-
binase by the laboratory of Klaus 
Rajewsky, then at the University of 
Koln (Gu et al., 1994). By placing Cre 
recombinase under the control of a 
tissue-specific or stage-specific pro-
moter and flanking the gene to be tar-
geted with the loxP sites recognized 
by Cre, researchers could choose 
the timing and location of deletion of 
the gene of interest. These and other 
variations on gene-targeting tech-
niques have led to the establishment 
of an estimated 500 mouse models of 
human diseases ranging from cancer, 
diabetes, and cardiovascular disease 
to neurological ailments. In addition 
to the basic research conducted on 
these mutants, pharmaceutical com-
panies frequently use them to aid in 
drug discovery and testing.
From Knockout Mice to Healthier 
Humans
Like all outstanding work, the dis-
covery of mouse ES cells and gene 
targeting has had an impact much 
greater than what might have been 
expected. Many researchers muse 
that parallel studies of human ES 
cells could perhaps move us closer 
to understanding true human traits. 
Such understanding could some day 
spur the use of this technology for 
the purposes of regenerative medi-
cine. However, such research would 
entail the manipulation of human ES 
cells, a procedure that is considered 
unethical in many countries today. It 
is unlikely that this controversy will 
evaporate in the near future because 
gene-targeting techniques currently 
rely on ES cells, and human ES cells 
can only be derived from human 
embryos. However, several groups of 
investigators made a discovery last 
year that promises to provide a sur-
rogate approach to studying human 
embryonic development and physiol-
ogy without having to directly inves-
tigate human ES cells. Working in 
mice, teams led by Shinya Yamanaka 
of Kyoto University, Rudolph Jae-
nisch at the Massachusetts Institute 
of Technology, and Kathrin Plath of 
the University of California at Los 
Angeles and Konrad Hochedlinger of 
the Massachusetts General Hospi-
tal have found that a small percent-
age of murine skin fibroblasts can be 
transduced to revert to multipotent 
stem cells by the introduction of only 
four transcription factors (Rossant, 
2007). These “reprogrammed” cells, 
which are termed “induced pluripo-
tent stem cells,” are quite similar in 
their properties to ES cells but are less tumorigenic than teratocarci-
noma cells. Just three weeks ago, 
the laboratories of Shinya Yamanaka 
and James Thomson of the Genome 
Center of Wisconsin reported using 
a similar transduction approach to 
generate induced pluripotent stem 
cells from human somatic cells (Taka-
hashi et al., 2007; Yu et al., 2007). 
These human ES-like cells express 
ES cell-surface markers, have normal 
karyotypes, express telomerase, and 
are capable of differentiating into cell 
types of all three germ layers. This 
exciting scientific advance means 
that it may soon be possible to pro-
vide patients with multipotent stem 
cells tailored for a given therapeutic 
purpose. Because these ES-like cells 
would have been generated from the 
patient’s own fibroblasts, the chance 
of the patient’s immune system 
rejecting them upon transplantation 
would be minimal. Even more satisfy-
ing may be the prospect that, using 
the homologous recombination pro-
cedure established by Capecchi and 
Smithies, ill effects from aberrations 
present in the germline of patients 
might be treated using tissue-specific 
ES-like cells. These possibilities show 
that the work of Evans, Capecchi, and 
Smithies has boundless implications 
for the scientific, medical, and ethical 
arenas.
As we move into the second cen-
tury of studying mouse genetics, we 
eagerly await the next great discov-
eries in murine and human genetic 
manipulation that will further advance 
medical science. By awarding the 
2007 Nobel Prize to the discoverers of 
knockout mice, the international com-
munity has vindicated Little’s original 
faith in the power of small creatures Cell 131, Deceto greatly benefit human health. Many 
believe that the 21st century will be 
the era in which studies of human 
genetics lead directly to regenerative 
medicine. If so, Little’s conviction will 
have been validated beyond his fond-
est imaginings.
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